Current and historical daily PE Ratio for Immunic Inc (
STU:10VA
) from 2015 to May 29 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Immunic stock (STU:10VA) PE ratio as of May 29 2024 is 0.
More Details
Immunic Inc (STU:10VA) PE Ratio (TTM) Chart
Immunic Inc (STU:10VA) PE Ratio (TTM) Historical Data
View and export this data going back to 2015. Start your Free Trial
Total 1236
- 1
- 2
- 3
- 4
- 5
- 6
- 14
| Immunic PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2024-05-29 | At Loss | 2024-03-22 | At Loss |
| 2024-05-28 | At Loss | 2024-03-21 | At Loss |
| 2024-05-27 | At Loss | 2024-03-20 | At Loss |
| 2024-05-24 | At Loss | 2024-03-19 | At Loss |
| 2024-05-23 | At Loss | 2024-03-18 | At Loss |
| 2024-05-22 | At Loss | 2024-03-15 | At Loss |
| 2024-05-21 | At Loss | 2024-03-14 | At Loss |
| 2024-05-20 | At Loss | 2024-03-13 | At Loss |
| 2024-05-17 | At Loss | 2024-03-12 | At Loss |
| 2024-05-16 | At Loss | 2024-03-11 | At Loss |
| 2024-05-15 | At Loss | 2024-03-08 | At Loss |
| 2024-05-14 | At Loss | 2024-03-07 | At Loss |
| 2024-05-13 | At Loss | 2024-03-06 | At Loss |
| 2024-05-10 | At Loss | 2024-03-05 | At Loss |
| 2024-05-09 | At Loss | 2024-03-04 | At Loss |
| 2024-05-08 | At Loss | 2024-03-01 | At Loss |
| 2024-05-07 | At Loss | 2024-02-29 | At Loss |
| 2024-05-06 | At Loss | 2024-02-28 | At Loss |
| 2024-05-03 | At Loss | 2024-02-27 | At Loss |
| 2024-05-02 | At Loss | 2024-02-26 | At Loss |
| 2024-04-30 | At Loss | 2024-02-23 | At Loss |
| 2024-04-29 | At Loss | 2024-02-22 | At Loss |
| 2024-04-26 | At Loss | 2024-02-21 | At Loss |
| 2024-04-25 | At Loss | 2024-02-20 | At Loss |
| 2024-04-24 | At Loss | 2024-02-19 | At Loss |
| 2024-04-23 | At Loss | 2024-02-16 | At Loss |
| 2024-04-22 | At Loss | 2024-02-15 | At Loss |
| 2024-04-19 | At Loss | 2024-02-14 | At Loss |
| 2024-04-18 | At Loss | 2024-02-13 | At Loss |
| 2024-04-17 | At Loss | 2024-02-12 | At Loss |
| 2024-04-16 | At Loss | 2024-02-09 | At Loss |
| 2024-04-15 | At Loss | 2024-02-08 | At Loss |
| 2024-04-12 | At Loss | 2024-02-07 | At Loss |
| 2024-04-11 | At Loss | 2024-02-06 | At Loss |
| 2024-04-10 | At Loss | 2024-02-05 | At Loss |
| 2024-04-09 | At Loss | 2024-02-02 | At Loss |
| 2024-04-08 | At Loss | 2024-02-01 | At Loss |
| 2024-04-05 | At Loss | 2024-01-31 | At Loss |
| 2024-04-04 | At Loss | 2024-01-30 | At Loss |
| 2024-04-03 | At Loss | 2024-01-29 | At Loss |
| 2024-04-02 | At Loss | 2024-01-26 | At Loss |
| 2024-03-28 | At Loss | 2024-01-25 | At Loss |
| 2024-03-27 | At Loss | 2024-01-24 | At Loss |
| 2024-03-26 | At Loss | 2024-01-23 | At Loss |
| 2024-03-25 | At Loss | 2024-01-22 | At Loss |
Immunic Inc (STU:10VA) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
Immunic Inc
NAICS : 541714
SIC : 2834
ISIN : US92847R1041
Description
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers